Long-term results of stereotactic body radiation therapy in medically inoperable stage I non–small cell lung cancer
Ces deux études évaluent, du point de vue notamment du contrôle de la maladie et des événements indésirables, l'intérêt d'une radiothérapie corporelle stéréotaxique pour traiter un cancer du poumon non à petites cellules opérable (26 patients ; âge médian : 72,5 ans) ou inopérable (55 patients ; durée médiane de suivi : 48 mois)
In 2010, NRG Oncology published the initial results (3-year data) of their multicenter, single-arm, phase 2 NRG Oncology RTOG 0236 trial using sterotactic body radiation therapy (SBRT) to achieve a potent dose in patients with medically inoperable, clinically staged early lung cancer.1 Despite its rapid acceptance as a standard treatment, the implementation of SBRT into clinical practice has been incomplete.2 Patients enrolled in the NRG Oncology RTOG 0236 trial continued to be followed up per protocol for tumor control, toxic effects, and survival.3 In this report, we describe 5-year results specifically to understand how potential late events may influence the utility of SBRT for this frail population.